A team of chemists in China has designed a family of tin-based compounds that outperform the frontline chemotherapy drug cisplatin in laboratory tests against several cancer cell lines. The new molecules, described in the Journal of Saudi Chemical Society, combine a dimethyltin(IV) core with derivatives of cinnamic acid, a natural plant compound already known for its antibacterial, antiviral, and antitumor properties. The most active member of the series, a 2-bromo-substituted complex labeled C1, killed HepG2 liver cancer cells at a concentration of just 1.86 micromolar, while requiring roughly five and a half times that dose to affect normal human liver cells. That selectivity gap, if it holds up in further studies, is exactly what drug developers hope to see from a candidate metallodrug.
Organotin compounds have long intrigued medicinal chemists because of their structural versatility and pronounced biological activity, but translating that raw potency into safe therapies has proven difficult. The type and number of organic groups attached to the tin atom strongly influence both cytotoxicity and selectivity, and diorganotin species of the form R2SnX2 generally offer the best balance between killing cancer cells and sparing healthy tissue. Methyl, butyl, and phenyl substituents each tune the Lewis acidity of the central tin and the spatial shape of the complex, which in turn governs how the molecule engages biological targets. The problem, the researchers note, is that the quantitative relationship between structure and activity remains stubbornly hard to predict, which is why systematic comparisons of closely related complexes matter for the field.
To build the new compounds, the team refluxed dimethyltin oxide with a series of substituted cinnamic acids in methanol under a strict 2:1 stoichiometry. The reaction proved remarkably reliable: five distinct complexes, C1 through C5, crystallized in yields of 80 to 86 percent after the filtrate was left to stand at room temperature for several days. The mild conditions and simple operation suggest the route is a general one for constructing this class of tetranuclear tin oxide clusters. Infrared spectroscopy provided the first confirmation that coordination had occurred, with the carboxylate stretching band shifting from the 1700 to 1725 wavenumber range typical of free carboxylic acids down to about 1640, a redshift that signals successful binding to the tin center.
Single-crystal X-ray diffraction revealed that all five complexes share a striking common architecture: a ladder-like Sn4O4 core built from three edge-sharing Sn2O2 rhomboids. The central ring features notably shorter tin-oxygen bonds, between 2.024 and 2.040 angstroms, than the terminal rings, which measure 2.217 to 2.254 angstroms. That contraction reflects the triple-bridging mode of the central oxygen atoms, which link three metal centers each and impose distinctive electronic and steric constraints. Perhaps the most intriguing structural detail is that the terminal, electrophilic tin atoms are capped exclusively by methoxy ligands generated in situ from the methanol solvent, rather than by the carboxylate groups of the cinnamate ligands, a clear example of site selectivity during the self-assembly process.
The two kinds of tin centers in each cluster adopt different geometries. Those in the central ring are five-coordinate with a trigonal bipyramidal arrangement, bound to two bridging oxygens, two methyl groups, and one methoxy ligand. The terminal tin atoms are six-coordinate and distorted octahedral, carrying a chelating carboxylate in addition to the other ligands. Nuclear magnetic resonance data corroborate this picture: the 119Sn spectra of all five complexes show two resonances, near minus 136 and minus 173 parts per million, consistent with coexisting five- and six-coordinate tin centers. Thermogravimetric analysis traced decomposition through loss of methoxy ligands near 100 degrees Celsius followed by pyrolysis of the organic framework, leaving a residue whose mass matched the theoretical yield of tin dioxide.
Before any biological claims could be made, the team needed to know whether the lead complex would survive in the body’s aqueous environment. Ultraviolet-visible spectroscopy showed that C1’s absorption profile is essentially identical in ethanol and in a dilute ethanol-Tris buffer, and the spectrum barely changes across pH values from 3 to 10, a range that spans the acidic microenvironment of tumors to physiological pH. Over 24 hours at pH 7.4, absorbance declined only slightly. Hirshfeld surface analysis of the crystal packing of C1, meanwhile, quantified the intermolecular forces holding the lattice together, finding that hydrogen-hydrogen van der Waals contacts dominate at 63.3 percent, followed by carbon-hydrogen contacts at 15.9 percent and bromine-hydrogen contacts at 8.9 percent.
The mechanistic core of the study concerns how C1 interacts with DNA. Ultraviolet titration showed the complex’s 300-nanometer absorption band shifting about 5 nanometers to the red and diminishing in intensity as DNA concentration rose, behavior characteristic of a planar molecule slipping between stacked base pairs through pi-pi interactions. The calculated binding constant of 1.22 times 10 to the fourth liters per mole falls squarely in the range of established intercalators. A competitive assay using ethidium bromide, a fluorescent dye that fluoresces only when intercalated into DNA, showed dose-dependent quenching as C1 displaced the dye from the helix, with a Stern-Volmer constant of 2.04 times 10 to the fourth. Viscosity measurements sealed the case: DNA viscosity rose sharply with increasing C1 concentration, far more than with the free cinnamic acid ligand or dimethyltin oxide alone, because intercalation lengthens the helix and increases its hydrodynamic volume.
Molecular docking simulations added atomic-level texture to the picture. The optimized binding pose shows the planar cinnamate moiety of C1 slotting coplanar between DNA base pairs, while the tin-bound methyl groups split their duties: some project into the minor groove to make van der Waals contacts, and others point outward to avoid clashing with the phosphate backbone. In cell-based assays against MCF-7 breast cancer, HepG2 liver cancer, and NCI-H460 lung cancer lines, every complex beat cisplatin by a wide margin. Substituent effects were decisive. The 2-bromo derivative C1 led with IC50 values of 3.04, 1.86, and 4.78 micromolar across the three lines, likely because bromine’s electron-withdrawing character and halogen-bonding capacity improve target affinity. The 2,6-dichloro complex C4 followed closely, while the alpha-methyl derivative C5 was weakest, its electron-donating group apparently disrupting favorable interactions.
Flow cytometry revealed how the cells actually die. Using Annexin V-FITC and propidium iodide dual staining, the researchers showed that C1 triggers apoptosis in a dose-dependent fashion in HepG2 cells: 21.26 percent of the population after 48 hours at 1 micromolar, 35.6 percent at 2 micromolar, and 53.6 percent at 4 micromolar. Cell-cycle analysis showed a corresponding concentration-dependent accumulation of cells in the G2/M phase, with depletion of the G0/G1 and S populations. That arrest pattern suggests C1 interferes with mitotic machinery or introduces DNA lesions that activate the cell’s damage response; when the damage cannot be repaired, the intrinsic apoptotic pathway takes over. This coupling of cycle disruption to programmed death offers a coherent mechanistic account of the compound’s antiproliferative power.
The authors position C1 as a high-activity lead for the design of next-generation metallodrugs, emphasizing that its cytotoxicity arises from a synergistic interplay of mechanisms rather than a single target. The work also fills a gap in the organotin literature: while dibutyltin and tricyclohexyltin cinnamates have been systematically studied, dimethyltin analogues remained scarce. The Hunan-based team, funded by the Hunan Provincial Natural Science Foundation, argues that systematically mapping how substituent type and position modulate activity is the surest path from laboratory curiosity to clinical candidate. Considerable distance remains between potent in vitro activity and an approved medicine, and organotin compounds carry well-known toxicity concerns that selectivity data alone cannot resolve. Still, a molecule that is stable across physiological pH, intercalates DNA by a classical mechanism, arrests cancer cells in mitosis, and spares normal liver cells at therapeutic concentrations gives medicinal chemists a concrete scaffold to optimize.
Subject of Research: Synthesis, crystal structures, and anticancer activity of tetranuclear dimethyltin(IV)-cinnamate complexes with ladder-type Sn4O4 clusters
Article Title: Tetranuclear dimethyltin(IV)-cinnamate complexes with a ladder-type Sn4O4 cluster: synthesis, crystal structures, and anticancer activity
Article References: Zhang, Z., Jiang, Z., Tan, Y., Tan, Y., & Jiang, W. (2026). Tetranuclear dimethyltin(IV)-cinnamate complexes with a ladder-type Sn4O4 cluster: synthesis, crystal structures, and anticancer activity. Journal of Saudi Chemical Society, 30(5), Article 75. https://doi.org/10.1007/s44442-026-00129-y
Image Credits: AI Generated
DOI: 10.1007/s44442-026-00129-y
Keywords: organotin, dimethyltin, cinnamic acid, anticancer, Sn4O4 cluster, DNA intercalation, cisplatin, HepG2, apoptosis, cell cycle arrest, crystal structure, metallodrugs
Cite Scienmag News
APA
MLA
Chicago
Bethany Barker. (September 30, 2026). Tin-Based Ladder Clusters Show Potent Anticancer Activity Beyond Cisplatin. Scienmag. https://scienmag.com/tin-based-ladder-clusters-show-potent-anticancer-activity-beyond-cisplatin/
Bethany Barker. “Tin-Based Ladder Clusters Show Potent Anticancer Activity Beyond Cisplatin.” Scienmag, 30 September 2026, https://scienmag.com/tin-based-ladder-clusters-show-potent-anticancer-activity-beyond-cisplatin/. Accessed 30 September 2026.
Bethany Barker. “Tin-Based Ladder Clusters Show Potent Anticancer Activity Beyond Cisplatin.” Scienmag. September 30, 2026. https://scienmag.com/tin-based-ladder-clusters-show-potent-anticancer-activity-beyond-cisplatin/
Copy citation
Download RIS
Tags: anticancerapoptosiscell cycle arrestchemical design of metallodrugscinnamic acidcisplatincisplatin alternative therapiescrystal structuredimethyltinDNA intercalationdrug development for selective cancer targetingHepG2laboratory testing of tin-based anticancer compoundslong-twentieth century organometallic anti-cancer agentsmetallodrugsnatural cinnamic acid derivativesorganotinorganotin medicinal chemistryselective cytotoxicity in cancer treatmentSn4O4 clusterstructure-activity relationship of organotin compoundstherapeutic potential of organotin compoundstin complexes against liver cancertin-based anticancer compounds
